XMD8-87 is a tyrosine kinase nonreceptor 2 (TNK2) inhibitor with IC50s of 38 nmol/L and 113 nmol/L for the D163E and R806Q mutations.

XMD16-5 is an inhibitor of TNK2 with IC50 value of 0.38µM, potently inhibiting phosphorylation of TNK2 truncation mutations found in solid tumor types.

AIM-100 is a potent and selective Ack1 (TNK2) inhibitor with IC50 value of 22nM, showing suppression phosphorylation of Tyr267 of the androgen receptor in prostate cancer cells.

KRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively and displays drug-like properties without hERG liability.